Patents by Inventor Eisuke Mekada

Eisuke Mekada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYPEPTIDE AND ANTI-TUMOR AGENT
    Publication number: 20170029474
    Abstract: Provided is a polypeptide comprising an R domain of CRM197 and comprising one or more amino acid substitutions or deletions at positions selected from the group consisting of 391, 460, 466, 467, 468, 472, 507, and 520 of the R domain.
    Type: Application
    Filed: October 8, 2014
    Publication date: February 2, 2017
    Inventor: Eisuke MEKADA
  • MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR
    Publication number: 20130337505
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a method for producing a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Application
    Filed: March 23, 2012
    Publication date: December 19, 2013
    Applicant: KYOWA HAKKO KIRIN, CO., LTD.
    Inventors: Eisuke MEKADA, Ryo IWAMOTO, Shingo MIYAMOTO, Kenya SHITARA, Akiko FURUYA, Kazuyasu NAKAMURA, Kumiko TAKAHASHI, Hiroshi ANDO, Kazuhiro MASUDA, Yuka SASAKI
  • Anticancer agent
    Patent number: 8507443
    Abstract: The present invention is an antineoplastic agent characterized by including at least one of taxol and taxol derivatives and a protein which is a mutant of diphtheria toxin, having an activity to inhibit a binding between HB-EGF and EGFR and substantially not having a toxicity of diphtheria toxin as active ingredients.
    Type: Grant
    Filed: August 19, 2005
    Date of Patent: August 13, 2013
    Assignee: The Research Foundation for Microbial Diseases of Osaka University
    Inventors: Eisuke Mekada, Shingo Miyamoto
  • Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
    Patent number: 8481039
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: July 9, 2013
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Eisuke Mekada, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki
  • MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR
    Publication number: 20120177649
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Application
    Filed: February 3, 2012
    Publication date: July 12, 2012
    Applicant: KYOWA HAKKO KIRIN, CO., LTD.
    Inventors: Eisuke MEKADA, Ryo IWAMOTO, Shingo MIYAMOTO, Kenya SHITARA, Akiko FURUYA, Kazuyasu NAKAMURA, Kumiko TAKAHASHI, Hiroshi ANDO, Kazuhiro MASUDA, Yuka SASAKI
  • Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
    Patent number: 8173781
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: May 8, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Eisuke Mekada, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki
  • Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
    Patent number: 8163282
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: April 24, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Eisuke Mekada, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki
  • HB-EGF BOUND PROTEIN COMPLEX
    Publication number: 20120027843
    Abstract: A complex essentially comprising a protein having an action of binding to a membrane-bound HB-EGF to promote the uptake of the membrane-bound HB-EGF by cells, and a carrier.
    Type: Application
    Filed: February 3, 2010
    Publication date: February 2, 2012
    Inventors: Tetsuo Minamino, Eisuke Mekada, Asai Tomohiro, Seiji Takashima, Yoshihiro Asano
  • Anticancer Agent
    Publication number: 20110230418
    Abstract: The present invention is an antineoplastic agent characterized by including at least one of taxol and taxol derivatives and a protein which is a mutant of diphtheria toxin, having an activity to inhibit a binding between HB-EGF and EGFR and substantially not having a toxicity of diphtheria toxin as active ingredients.
    Type: Application
    Filed: August 19, 2005
    Publication date: September 22, 2011
    Applicant: The Research Foundation For Microbial Diseases Of Osaka University
    Inventors: Eisuke Mekada, Shingo Miyamoto
  • MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR
    Publication number: 20110052595
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Application
    Filed: June 30, 2009
    Publication date: March 3, 2011
    Applicant: KYOWA HAKKO KIRIN CO., LTD
    Inventors: Eisuke MEKADA, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki
  • MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR
    Publication number: 20110034673
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Application
    Filed: October 30, 2009
    Publication date: February 10, 2011
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Eisuke MEKADA, Ryo IWAMOTO, Shingo MIYAMOTO, Kenya SHITARA, Akiko FURUYA, Kazuyasu NAKAMURA, Kumiko TAKAHASHI, Hiroshi ANDO, Kazuhiro MASUDA, Yuka SASAKI
  • Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
    Patent number: 7851601
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Grant
    Filed: December 8, 2008
    Date of Patent: December 14, 2010
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Eisuke Mekada, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki
  • MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR
    Publication number: 20100184958
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Application
    Filed: December 8, 2008
    Publication date: July 22, 2010
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: EISUKE MEKADA, RYO IWAMOTO, SHINGO MIYAMOTO, KENYA SHITARA, AKIKO FURUYA, KAZUYASU NAKAMURA, KUMIKO TAKAHASHI, HIROSHI ANDO, KAZUHIRO MASUDA, YUKA SASAKI
  • Therapeutic agent for cancer
    Patent number: 7700546
    Abstract: The present invention provides a cancer therapeutic agent containing as an active ingredient a substance, particularly CRM197 which inhibits the binding of HB-EGF to EGF receptor by binding to HB-EGF, wherein a cancer is selected from the group consisting of a bladder cancer, a colon cancer or peritoneal metastatic cancers of a stomach cancer and a pancreatic cancer.
    Type: Grant
    Filed: June 20, 2006
    Date of Patent: April 20, 2010
    Assignee: The Research foundation for Microbial Diseases of Osaka c/o Osaka University
    Inventors: Eisuke Mekada, Shingo Miyamoto
  • CD9/CD81 double-deficient non-human animal
    Patent number: 7659441
    Abstract: An object of the invention is to provide a non-human animal which can be utilized as a model animal well exhibiting a pathological condition of low-turnover type of osteoporosis and chronic obstructive pulmonary disease, for screening therapeutic agents for osteoporosis or therapeutic agents for chronic obstructive pulmonary disease, etc. The invention includes a non-human animal, wherein a gene coding for CD9 and a gene coding for CD81 are deficient at least in somatic cells; and a method to use the non-human animal as an osteoporosis model animal, including a step of measuring the degree of inhibition in the osteogenesis, and a method to use the non-human animal as a chronic obstructive pulmonary disease model animal, including a step of measuring the degree of a phenotype similar to chronic obstructive pulmonary disease.
    Type: Grant
    Filed: December 5, 2005
    Date of Patent: February 9, 2010
    Assignee: Osaka Industrial Promotion Organization
    Inventors: Eisuke Mekada, Kenji Miyado, Isao Tachibana, Yoshito Takeda
  • Therapeutic Agent for Cancer
    Publication number: 20090105135
    Abstract: The present invention provides a cancer therapeutic agent containing as an active ingredient a substance, particularly CRM197 which inhibits the binding of HB-EGF to EGF receptor by binding to HB-EGF, wherein a cancer is selected from the group consisting of a bladder cancer, a colon cancer or peritoneal metastatic cancers of a stomach cancer and a pancreatic cancer.
    Type: Application
    Filed: June 20, 2006
    Publication date: April 23, 2009
    Applicant: The Research Foundation for Microbail Diseases of Osaka University
    Inventors: Eisuke Mekada, Shingo Miyamoto
  • CD9/CD81 double-deficient non-human animal
    Publication number: 20060288435
    Abstract: An object of the invention is to provide a non-human animal which can be utilized as a model animal well exhibiting a pathological condition of low-turnover type of osteoporosis and chronic obstructive pulmonary disease, for screening therapeutic agents for osteoporosis or therapeutic agents for chronic obstructive pulmonary disease, etc. The invention includes a non-human animal, wherein a gene coding for CD9 and a gene coding for CD81 are deficient at least in somatic cells; and a method to use the non-human animal as an osteoporosis model animal, including a step of measuring the degree of inhibition in the osteogenesis, and a method to use the non-human animal as a chronic obstructive pulmonary disease model animal, including a step of measuring the degree of a phenotype similar to chronic obstructive pulmonary disease.
    Type: Application
    Filed: December 5, 2005
    Publication date: December 21, 2006
    Applicant: OSAKA INDUSTRIAL PROMOTION ORGANIZATION
    Inventors: Eisuke Mekada, Kenji Miyado, Isao Tachibana, Yoshito Takeda
  • Anti-cancer agents
    Publication number: 20060270600
    Abstract: An anti-cancer agent comprising as an active component a protein which is a diphtheria toxin mutant such as CRM197, has an activity to inhibit binding of HB-EGF to an EGR receptor and substantially does not have toxicity of diphtheria toxin. The anti-cancer agent is particularly effective for the treatment of ovarian cancer, breast cancer and prostate cancer.
    Type: Application
    Filed: May 23, 2006
    Publication date: November 30, 2006
    Inventors: Eisuke Mekada, Shingo Miyamoto